BMJ open gastroenterology
Cure8 research brief
Why This Matters
This real-world multicentre study evaluates risankizumab effectiveness and short-term persistence in adults with Crohn's disease, including those previously treated with ustekinumab — information that can help patients and clinicians weigh treatment expectations.
Who Should Pay Attention
Adults with Crohn's disease (including those previously on biologics), clinicians managing IBD, and researchers focused on biologic therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study included 131 adults with Crohn's disease across nine hospitals in North West England treated between May 2024 and April 2025. Six-month treatment persistence was 91% and steroid-free persistence 84%. Among patients with paired data, median CRP and faecal calprotectin fell between baseline and 6 months.
Around two-thirds of a small clinical subgroup achieved steroid-free clinical remission; biochemical remission was achieved in a smaller proportion. Prior exposure to ustekinumab did not appear to change persistence or remission rates. No new safety signals were reported in this cohort.
The findings are from a retrospective observational study and reflect routine clinical practice rather than a randomized trial. Individual responses vary, and the study reports short-term (6-month) outcomes; longer-term effectiveness and safety require further follow-up.
Keep In Mind
Retrospective real-world data reflect clinical practice but have inherent limitations (selection bias, missing data). The study reports 6-month outcomes; longer-term effectiveness and safety remain to be seen.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationBMJ open gastroenterology
AuthorsThomas D Butler, Anthony Beard, Abosede Ososanya +19 more
InstitutionDivision of Diabetes, Endocrinology and Gastroenterology, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK tom.butler@manchester.ac.uk.
Study typeJournal article, multicenter study
Indexed viaPubMed
Source typeResearch paper
PublishedAug 19, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Competing interests: TDB has received travel reimbursement from Galapagos and Celltrion, Inc. TDB is an associate editor at BMJ Open Gastroenterology; he was not involved in the handling of this manuscript by the journal. JK has received consultation, speaker fee and travel grants from Abbvie, BMS, Celltrion, Dr Falk, Ferring, J&J, Lilly, Takeda, Tillotts. JM has received travel grants from Alfasigma, AbbVie, Johnson & Johnson, Tillotts; has received advisory fees from Amgen, Takeda; and has received speaker fees from Dr Falk and AbbVie. KK has received consultancy, educational and travel grants from Abbvie, Takeda, Tillotts, Galapagos, Janssen/Johnson & Johnson, BMS, Dr Falk, Lilly. EN has received consultation and speaker fees and travel grants from AbbVie, Dr Falk, J&J, Lilly, Takeda and Tillotts. AKK has received speaker fee, travel and educational support from Dr Falk Pharma, Takeda and Lilly. CO has received educational and travel grants from AbbVie and Alphasigma. KC has received travel grants from Abbvie and Eli Lilly. BC has received speaker fees from AbbVie and Dr Falk Pharma and received travel reimbursement from Ferring and Lilly. JKL has received speaker and consultancy fees from AbbVie, Abivax, Arena, Alfasigma, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Johnson & Johnson, Merck Sharpe Dohme, Pfizer and Takeda and research funds from Galapagos and Takeda. KW has received speaker fee from Janssen-Cilag, travel reimbursement from Dr Falk Pharma, Tillotts Pharma. The other authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Prospective real-world experience with risankizumab in difficult-to-treat Crohn’s disease: results from the Dutch Initiative on Crohn and Colitis Registry
The study provides real-world effectiveness and safety data for risankizumab in a largely difficult-to-treat Crohn's population, showing about half achieved corticosteroid-free clinical remission at 24 weeks —...
Beyond Anti-TNF: Is Ustekinumab a Better Choice in Crohn's? - Medscape
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
Differentiating IL-23 Inhibitors in Crohn's Disease | Drugs
IL‑23 inhibitors are an important and growing class of drugs for Crohn’s disease. Comparing them helps patients and clinicians understand differences in trial results, approvals, and possible treatment choices.